THERAPIX BIOSCI/S (NASDAQ:TRPX) released its quarterly earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.24, Fidelity Earnings reports.

TRPX stock opened at $3.60 on Tuesday. THERAPIX BIOSCI/S has a 52-week low of $3.00 and a 52-week high of $7.69. The company has a market cap of $12.48 million, a PE ratio of 1.68 and a beta of 1.07.

THERAPIX BIOSCI/S Company Profile

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Further Reading: Should you buy a closed-end mutual fund?

Earnings History for THERAPIX BIOSCI/S (NASDAQ:TRPX)

Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.